Experienced in Squamous Cell Lung Carcinoma

Haruhiro Saito

Yokohama, JP 
Experienced in Squamous Cell Lung Carcinoma
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Haruhiro Saito practices in Yokohama, Japan. Saito is rated as an Experienced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

Their clinical research consists of co-authoring 99 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Squamous Cell Lung Carcinoma.

Locations

Yokohama, Japan
Other Locations
Tokyo, 1130032, Japan
Kanagawa, Japan
Ube, Japan
Yaizu, 4250013, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3

99 Total Publications

Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors.
Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors.
Journal: Frontiers in immunology
Published: July 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Saito's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile